 

The transcript highlights the financial performance of West Pharmaceutical Services, Inc. in the first quarter of 2020. Despite the challenges posed by the COVID-19 pandemic, West has maintained operations at normal capacity and has been able to leverage its global manufacturing network to meet the increase in demand for its products. The company has experienced strong growth in organic sales and adjusted earnings per share, driven by the growth in high-value products and the expansion of its Proprietary Products gross profit margin. West has also maintained a strong balance sheet, generating $57.1 million in operating cash flow and has a full-year 2020 net sales guidance of between $1.95 billion and $1.97 billion, with an estimated organic sales growth of approximately 8%. The company is committed to supporting the healthcare industry in the fight against the COVID-19 pandemic and is dedicated to ensuring continuity of supply to its customers.